User login

ARDSNet

Home

LARMA

Lisofylline for ALI/ARDS

Submitted by Nancy Ringwood on Mon, 2011-06-06 13:15

The LARMA study was a randomized, double-blind, placebo- controlled multi-center 2 x 2 factorial study where each patient was randomized between Lisofylline and Placebo. It was designed to test whether the administration of lisofylline early after the onset of ALI or ARDS would reduce mortality and morbidity.

Lysophylline for ALI/ARDS

The LARMA study was a randomized, double-blind, placebo- controlled multi-center 2 x 2 factorial study where each patient was randomized between Lisofylline and Placebo. It was designed to test whether the administration of lisofylline early after the onset of ALI or ARDS would reduce mortality and morbidity.

LARMA Study Synopsis

A Phase II/III Randomized, Double-Blind, Placebo-Controlled Trial of Lisofylline in Patients with Acute Lung Injury and Adult Respiratory Distress Syndrome (LARMA)

This study was a randomized, double-blind, placebo- controlled multi-center 2 x 2 factorial study. Each patient is randomized between Lisofylline and Placebo.